Equities research analysts expect DENTSPLY SIRONA Inc (NASDAQ:XRAY) to post earnings of $0.59 per share for the current quarter, according to Zacks. Nine analysts have made estimates for DENTSPLY SIRONA’s earnings, with estimates ranging from $0.55 to $0.62. DENTSPLY SIRONA posted earnings of $0.65 per share in the same quarter last year, which would indicate a negative year over year growth rate of 9.2%. The business is expected to report its next earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that DENTSPLY SIRONA will report full year earnings of $2.57 per share for the current fiscal year, with EPS estimates ranging from $2.52 to $2.61. For the next year, analysts expect that the firm will report earnings of $2.84 per share, with EPS estimates ranging from $2.72 to $3.10. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Sunday, May 6th. The medical instruments supplier reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.03. The firm had revenue of $956.10 million during the quarter, compared to analysts’ expectations of $942.20 million. DENTSPLY SIRONA had a positive return on equity of 8.63% and a negative net margin of 38.32%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 EPS.
A number of brokerages have commented on XRAY. Zacks Investment Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Barclays reaffirmed a “hold” rating and set a $55.00 price target on shares of DENTSPLY SIRONA in a research report on Tuesday, May 8th. ValuEngine lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Robert W. Baird reduced their price objective on DENTSPLY SIRONA to $71.00 and set an “outperform” rating for the company in a research note on Tuesday, May 8th. Finally, BidaskClub upgraded DENTSPLY SIRONA from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. DENTSPLY SIRONA has a consensus rating of “Hold” and an average price target of $62.23.
In related news, Director Michael C. Alfano sold 1,404 shares of DENTSPLY SIRONA stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $45.83, for a total value of $64,345.32. Following the completion of the transaction, the director now owns 13,458 shares in the company, valued at approximately $616,780.14. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Nicholas W. Alexos purchased 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 9th. The stock was acquired at an average price of $44.71 per share, with a total value of $2,235,500.00. Following the purchase, the chief financial officer now owns 25,411 shares in the company, valued at $1,136,125.81. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 7,856 shares of company stock valued at $349,153. 1.93% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Focused Wealth Management Inc boosted its holdings in DENTSPLY SIRONA by 79.2% in the 4th quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock worth $171,000 after buying an additional 1,149 shares during the last quarter. Highland Capital Management LP acquired a new stake in DENTSPLY SIRONA in the 4th quarter worth about $230,000. IBM Retirement Fund boosted its holdings in DENTSPLY SIRONA by 49.1% in the 1st quarter. IBM Retirement Fund now owns 4,955 shares of the medical instruments supplier’s stock worth $249,000 after buying an additional 1,631 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in DENTSPLY SIRONA in the 4th quarter worth about $259,000. Finally, NuWave Investment Management LLC boosted its holdings in DENTSPLY SIRONA by 184.6% in the 1st quarter. NuWave Investment Management LLC now owns 5,237 shares of the medical instruments supplier’s stock worth $263,000 after buying an additional 3,397 shares during the last quarter. Hedge funds and other institutional investors own 93.80% of the company’s stock.
Shares of XRAY opened at $45.01 on Friday. DENTSPLY SIRONA has a one year low of $41.64 and a one year high of $68.98. The company has a quick ratio of 1.46, a current ratio of 2.23 and a debt-to-equity ratio of 0.25. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 2.32 and a beta of 1.23.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 13th. Investors of record on Friday, June 29th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $0.35 annualized dividend and a dividend yield of 0.78%. DENTSPLY SIRONA’s dividend payout ratio is presently 13.16%.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.